Author

Julian Panés

RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES

RELATIONSHIP BETWEEN DISEASE ACTIVITY AS ASSESSED BY THE MAYO SCORE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
RELATIONSHIP BETWEEN DISEASE ACTIVITY AS ASSESSED BY THE MAYO SCORE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés  et al.

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Novel integrin strategies
Novel integrin strategies

Julian Panés

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Julian Panés  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY

Julian Panés  et al.

LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE
LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE

Julian Panés  et al.

LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE
LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Julian Panés  et al.

MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES
MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian Panés  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES
MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY
INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY

Julian Panés  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

Julian Panés  et al.

Item 1 - 20 / 57
1
2 3